Why Patients Are Pivoting to Picosecond Lasers for Melasma

Melasma is one of the most searched pigment concerns in dermatology—and one of the hardest to keep faded. Older heat-heavy lasers and intense pulsed light can lighten patches, then trigger rebound darkening. That risk is why patients and clinics are pivoting to picosecond laser treatment for melasma.

From Heat to Shockwaves

Traditional Q-switched (nanosecond) lasers mainly heat melanin. Picosecond pulses last about a trillionth of a second. That speed favors a photoacoustic shockwave that breaks pigment into finer particles the body can clear, with less heat spreading into nearby skin. For a heat-sensitive condition like melasma, lower thermal load is the clinical advantage.

Shorter pulses also stay closer to the thermal relaxation time of melanosomes. In theory, that means more pigment shatter and less collateral inflammation—the pathway that often leads to post-inflammatory hyperpigmentation, especially on medium and deeper skin tones.

What Recent Studies Show

A 2026 review in Dermatologic Surgery found that picosecond devices can reduce melanin index and Melasma Area and Severity Index (MASI) scores, improve texture, and often do so with fewer adverse effects than older light-based options.

Head-to-head data is encouraging, though results vary by wavelength and protocol:

• A 2025 comparison reported that fractional 1,064 nm picosecond Nd:YAG lowered modified MASI faster than low-fluence Q-switched Nd:YAG (about 41% versus 30% after five sessions) and used lower energy.
• A 2025 randomized split-face study of low-fluence 1,064 nm picosecond laser plus a micro-lens array showed meaningful MASI drops, better texture and pores, and lower six-month recurrence on the array-treated side.
• A randomized trial in Fitzpatrick III–IV skin found non-fractional 1,064 nm picosecond Nd:YAG outperformed both 755 nm picosecond alexandrite and 2% hydroquinone on MASI, with similar safety.

Regulatory clearance has also changed demand. The U.S. Food and Drug Administration has cleared at least one picosecond platform (PicoWay) for melasma, moving the technology from experimental to routinely requested.

Why Patients Ask for Pico Now

Search interest follows lived experience. Patients are not only chasing clearance percentages. They want less sting and downtime than classic laser toning, a lower-heat option if they have had laser-triggered darkening before, and extra texture or pore improvement when fractionated or array handpieces are used.

Melasma still relapses. Hormones, heat, and ultraviolet light drive it. Lasers work best after pigment is calmed with topicals and only with daily broad-spectrum sunscreen. That honest framing is part of why picosecond protocols feel more trustworthy: they aim to chip away at pigment without pouring fuel on the fire.

What to Expect

A typical course is several conservative, low-fluence sessions spaced weeks apart—not one aggressive pass. Mild redness is common. Lasting hypopigmentation or scarring is uncommon when settings stay gentle. Maintenance and sun protection remain non-negotiable.

At Four Seasons Laser Center in Boca Raton, picosecond technology—including PicoFY™—is used for pigment as part of a customized plan, not as a one-size cure. If patches have stalled on creams alone, a consultation can determine whether a low-heat pico protocol fits your skin type. Learn more about picosecond options for melasma or book a free consultation.

Researched and written by Edilane Piedra.

Key References

1. Ridha Z, Kamrani P, Firsowicz M, et al. Laser and light-based therapies for treating melasma: an in-depth review. Dermatol Surg. 2026;52(4):355-362. https://pubmed.ncbi.nlm.nih.gov/41020517/
2. Efficacy and safety of low-fluence 1064 nm picosecond laser with/without micro-lens arrays for melasma. Lasers Med Sci. 2025. https://link.springer.com/article/10.1007/s10103-025-04655-w
3. Zhang X, et al. Comparison of fractional 1064 nm picosecond laser and low-fluence Q-switched Nd:YAG laser in melasma. J Cosmet Laser Ther. 2025. https://pubmed.ncbi.nlm.nih.gov/41841366/
4. Liang S, et al. Comparison of picosecond Nd:YAG 1,064 nm, picosecond alexandrite 755 nm, and 2% hydroquinone for melasma. Front Med. 2023. https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1132823/full
5. Dermatology Times. FDA clears PicoWay laser for melasma, lentigines, and more. https://www.dermatologytimes.com/view/fda-clears-picoway-laser-for-melasma-lentigines-and-more